Status and phase
Conditions
Treatments
About
ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
18 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Cara Casseday
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal